The company is filing an NDA for their antibacterial drug.
The filing has been promised by the company by the end of this month! 9/27 is the day
The release of a successful NDA filing by the end of this month will promote broad awareness and increase shareholder value.
Analysts have price targets in the range of 13.50-15.00 a share.
Here's the chart. IMO we will see a new 52 week high upon the date of the NDA filing.